Susceptibility-Weighted Imaging in Neurodegeneration

Susceptibility-Weighted Imaging in Neurodegeneration

Overview

Susceptibility-Weighted Imaging (SWI) is an advanced MRI technique that exploits magnetic susceptibility differences between tissues to visualize iron deposits, blood products, and calcifications with high sensitivity. In neurodegeneration, SWI has become essential for detecting brain iron accumulation — a hallmark of several movement disorders including Parkinson's disease, PSP, and CBD["@ward2020"].

Technical Principles

Physics Basis

Susceptibility-Weighted Imaging in Neurodegeneration

Overview

Susceptibility-Weighted Imaging (SWI) is an advanced MRI technique that exploits magnetic susceptibility differences between tissues to visualize iron deposits, blood products, and calcifications with high sensitivity. In neurodegeneration, SWI has become essential for detecting brain iron accumulation — a hallmark of several movement disorders including Parkinson's disease, PSP, and CBD["@ward2020"].

Technical Principles

Physics Basis

SWI uses a 3D gradient echo sequence with high spatial resolution and specific filtering to enhance the visibility of substances with different magnetic susceptibilities compared to surrounding tissue. The phase information from the MRI signal is used to create phase images that are sensitive to:

• Paramagnetic substances (iron, manganese): Create local magnetic field gradients that result in signal loss
• Diamagnetic substances (calcium): Cause opposite phase shifts
• Blood products (hemosiderin, ferritin): Strongly affect magnetic fields

Key Features

| Feature | Description | Clinical Utility |
|---------|-------------|------------------|
| Phase imaging | Extracts phase information sensitive to magnetic susceptibility | Detects iron/calcium |
| Magnitude images | Standard T2* weighted contrast | Anatomical detail |
| Minimum intensity projection (mIP) | Creates thin-slice projections | Enhances vein visibility |
| SWI filtered phase | High-pass filtered phase images | Improved iron quantification |

Applications in Neurodegeneration

Parkinson's Disease

In PD, SWI reveals:

• Nigrosome-1 loss: Loss of the "swallow tail sign" in the dorsolateral substantia nigra — a specific marker for dopaminergic neuron loss[@schwarz2014]
• Iron elevation: Increased iron in the substantia nigra (SN) and red nucleus, correlating with disease severity[@martin2020]
• Neuromelanin loss: Decreased signal in the locus coeruleus due to neuromelanin loss
• Levodopa-induced changes: Some studies show iron changes with chronic levodopa therapy

Progressive Supranuclear Palsy

PSP demonstrates characteristic SWI findings:

• Globus pallidus internus (GPi): Marked iron deposition — more severe than in PD[@bhattacharya2022]
• Subthalamic nucleus (STN): Iron accumulation contributes to the "Hummingbird sign" on conventional MRI
• Red nucleus: Significant iron deposition correlates with disease progression
• Midbrain: Iron elevation contributes to midbrain atrophy visualization
• Dentate nucleus: Iron in the deep cerebellar nuclei

Corticobasal Degeneration

CBD shows distinct patterns:

• Asymmetric iron deposition: More prominent in the hemisphere contralateral to the clinically affected side
• Frontoparietal regions: Iron in cortical and subcortical structures
• Basal ganglia: Variable iron accumulation in putamen and caudate
• Cortical involvement: Iron correlates with cortical atrophy patterns

Multiple System Atrophy

MSA exhibits:

• Putaminal atrophy: T2 hypointensity with iron deposition
• Cerebellar peduncles: Iron in the middle cerebellar peduncle ("hot cross bun" sign enhancement)
• Brainstem nuclei: Iron in the pontine nuclei and inferior olivary nucleus

Iron Quantification Methods

Visual Assessment

| Region | Normal | Mild Increase | Moderate | Severe |
|--------|--------|--------------|----------|--------|
| Substantia nigra | Isointense | Hypointense | Marked hypointensity | Black |
| Globus pallidus | Isointense | Hypointense | Marked hypointensity | Black |
| Red nucleus | Isointense | Hypointense | Marked hypointensity | Black |

Quantitative Methods

• R2* relaxometry: Measures relaxation rate proportional to iron concentration
• Quantitative susceptibility mapping (QSM): Reconstructs susceptibility maps from phase data for direct iron quantification[@liu2015]
• R2' (R2* - R2): Separates iron-related relaxation from myelin contributions
• Susceptibility tensor imaging (STI): Provides full tensor information for complex susceptibility sources

Clinical Protocol for CBS/PSP

Recommended SWI Protocol

| Sequence | Plane | Voxel Size | Clinical Utility |
|----------|-------|------------|------------------|
| SWI 3D | Axial | 0.5-1mm isotropic | Iron detection, venography |
| QSM | Axial | 0.5-1mm isotropic | Quantitative iron mapping |
| R2* mapping | Axial | 1mm isotropic | Relaxometry-based iron quant |

Recommended Timing

| Disease Stage | Frequency | Purpose |
|---------------|-----------|---------|
| Baseline | At diagnosis | Establish iron burden |
| 6 months | Early disease | Monitor change |
| Annually | Progressive disease | Track progression |

Diagnostic Utility

SWI in Differential Diagnosis

| Finding | PD | PSP | CBS | MSA |
|---------|----|----|-----|-----|
| Swallow tail loss | +++ | ++ | + (asymmetric) | + |
| GPi iron | + | +++ | ++ (asymmetric) | ++ |
| Midbrain iron | + | +++ | ++ | ++ |
| Asymmetry | - | - | +++ | - |

Sensitivity and Specificity

| Application | Sensitivity | Specificity | Notes |
|-------------|-------------|-------------|-------|
| PD vs. PSP | 85% | 80% | Combined with clinical |
| CBS vs. PSP | 75% | 70% | Asymmetry helps |
| Disease progression | 80% | N/A | Correlates with UPDRS |

Treatment Monitoring

Iron as Biomarker

Brain iron levels on SWI serve as potential biomarkers for:

• Disease progression: Iron accumulation correlates with clinical decline
• Treatment response: Some neuroprotective interventions may modulate iron
• Clinical trial endpoints: Iron imaging as secondary outcome measure

Drug Effects

| Intervention | Expected SWI Change | Evidence Level |
|--------------|-------------------|----------------|
| Deferiprone | Reduced brain iron | Moderate |
| CoQ10 | Potential iron modulation | Preliminary |
| Iron chelation | Decreased R2* | Phase 2 trials |

Integration with Other Imaging

Combined Protocol

| Modality | Information Gained | Synergy with SWI |
|----------|-------------------|------------------|
| DTI | White matter integrity | Iron affects diffusion |
| PET | Molecular pathology | Iron confirms neurodegeneration |
| MRI volumetrics | Atrophy patterns | Iron explains atrophy |
| Neuromelanin-MRI | Neuromelanin loss | Complementary to iron |

Multimodal Diagnosis

The combination of SWI + DTI + volumetric MRI provides:

Cost and Availability

| Aspect | Details |
|--------|---------|
| Cost | $500-1,500 (add-on to standard MRI) |
| Availability | Most MRI centers (3T required for best quality) |
| Insurance | Often covered for movement disorder workup |
| Time | 5-10 minutes additional scan time |

Patient Considerations

Contraindications

• Pacemakers: MRI conditional devices only
• Certain implants: Check compatibility
• Claustrophobia: May require open MRI or sedation

Preparation

• No specific preparation required
• Remove all metallic objects
• Remain still for 15-30 minutes

See Also

• Iron Accumulation in PSP
• Iron Homeostasis in Neurodegeneration
• Diffusion Tensor Imaging in Neurodegeneration
• Neuromelanin Imaging
• MRI Volumetrics
• Quantitative Susceptibility Mapping

References